Indication
B-cell non-Hodgkin lymphoma-refractory
2 clinical trials
2 products
1 drug
Clinical trial
Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
GolcadomideDrug
VarlilumabClinical trial
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39D, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-06-30
Product
LUCAR-G39D